iShs Biotechnology (IBB)
$137.04
0.00 (0.00%)
IBB Stock Quote Delayed 30 Minutes
Trade of the Day: iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB)
The Health Care ETF (IHF) broke down like a rented mule in early February following the breach of $110. Use IBB to trade this trend in biotech.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$137.86
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
647,847
Day's Range
$136.60 - $138.80
52-Week Range
$123.37 - $150.29
Dividend & Yield
$0.39 (0.28%)
IBB Stock Predictions, Articles, and iShs Biotechnology News
Trade of the Day: Inovio Pharmaceuticals (INO)
Trading biotech always carries risk but the rewards can be exciting if you can find momentum plays or companies with solid pipelines.
4 Healthcare Stocks on Shaky Ground – MRK LLY AZN BMY
Biotechnology stocks have broken down, and certain pharmaceutical stocks are now following suit. Could Merck and other pharmas suffer more downside?
The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is Ready to Bounce!
The IBB ETF of biotech stocks has reached support levels that could spark a better bounce. Active investors should take notice.
IBB: Biotech Stocks Find Their Magic Once More
Biotech stocks are percolating yet again. Embrace the newfound strength with this IBB ETF call spread.
Trade of the Day: BIIB Stock is Due for a Pop
Following a healthy correction, Biogen Inc. is poised to break through resistance.
Bear Down on Biotech Stocks Now (IBB)
Biotech stocks are well off their 2015 highs, but they could have further to fall. Get bearish on the biotech ETF IBB.
Wall Street Navigates Volatility as Rate Hike Nears
The psychology of the market remains out of whack as a December rate hike nears. Meanwhile, investors take shelter behind the volatility.
IBB: Another Biotech Bloodbath Beckons
Biotech stocks are poised for another downturn. Profit with this IBB stock put spread.
Why You Should Believe (and Buy) the Current Rebound in Biotech Stocks
Price gouging may have summoned Hillary Clinton's wrath, but the selloff in biotech stocks was built on fearmongering, while the rebound is being built on actual substance.
Stocks Surge to Start November
Investors look ahead to the remainder of the Q3 earnings season, a number of Fed speakers on Wednesday and the all-important October jobs report on Friday.
Gilead Sciences, Inc. – GILD Stock Catches the Bears Off Guard Again
Biotechnology stocks as a group are not yet out of the woods, but single-name stocks like GILD stock look promising right now.
Trade of the Day: IBB Still a Stellar Long-Term Buy
iShares NASDAQ Biotechnology Index (ETF) is headed for $400-plus.
Stocks Wilt on Earnings and Oil Decay
The short rally in stocks was stopped on several below-average earnings reports coupled with a downturn in oil. Housing starts, however, saw a nice gain.
Why Now Is the Time to Pile Back Into Biotech Stocks (IBB, XBI)
For years, biotech stocks have outperformed the market. In light of their recent downturn, now's a fine time to buy biotech ETFs like IBB and XBI.
Bet on a Bounce with These Biotech ETFs
Biotech stocks may have taken a beating lately, but that may just make these biotech ETFs more of a bargain.
Stocks Hit Resistance as Meltup Continues
Although the markets have seemed to rebound, the Dow is still down 5.1% YTD, the S&P 500 is dealing with resistance and Q3 looks weak.
Stocks Move Back in the Red Ahead of Earnings
Stocks took a haircut to move back in the red on continued weakness in biotech, while YUM and ADBE missed earnings and slashed guidance.
Be Careful Before Loving Leveraged Biotech ETFs
The new crop of triple-leveraged biotech ETFs have had staggering returns (and losses), serving as a reminder that not all investors should be involved with leveraged ETFs.
